UNSPSC 51433303: Hydralazine

This classification denotes an antihypertensive agent with the molecular formula C8H8N4, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 26NAK24LS8, chemically known as 1 (2h)-phthalazinone, hydrazone, monohydrochloride but generally known as hydralazine, which bears US NIH Compound Identifier 3637. European Medicines Agency schedules Hydralazine in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB08059MIG. The term HYDRALAZINE is an International Non-Proprietary Name.

UNSPSC 51433303 Hydralazine, a Commodity code, reflects state and local procurement of emergency and clinical medications for fire rescue, hospital, and health agency operations. State and local governments buy specific injectable medications—including hydralazine and related advanced life support drugs—in measured quantities for immediate operational use, typically through sealed-bid procurement tied to annual contracts with optional renewal periods. Issuing bodies include municipal fire departments, state health agencies, and multistate cooperative purchasing alliances. The City of Tampa's Fire Rescue department, the Texas Health and Human Services Commission, and the Minnesota Multistate Cooperative Purchasing Alliance (MMCAP) are representative recent buyers, indicating a mix of city fire services, state health administration, and cooperative purchasing vehicles spanning multiple jurisdictions and states.

Recent activity centers on Florida, Texas, and Minnesota. The City of Tampa issued IFB 26P00188 for Advanced Life Support Medications on April 24, 2026, with a response deadline of April 8, 2026, requesting 370 units of Labetalol, 1,810 units of Epinephrine, 330 units of Adenosine, and 1,020 units of Diltiazem for Tampa Fire Rescue at an estimated contract value of $40,000, with a Small Local Business Enterprise (SLBE) sheltered market designation offering a 5 percent bid discount capped at $10,000. The Texas HHS Commission posted RFI HHS0017013 on April 3, 2026, seeking vendor capabilities for direct-to-manufacturer prescription fulfillment outside traditional pharmacy benefit manager channels, signaling emerging state-level interest in procurement model innovation. The Minnesota Department of Administration's MMCAP issued RFP S1070000015802 due March 26, 2026, for generic multi-source pharmaceuticals and OTC products distributed across multiple state and local facilities in Minnesota and Oregon through authorized wholesalers, with a two-year contract term and performance penalties for late reporting or missed onboarding timelines.